NLS Pharmaceutics Jumps 4% On Getting FDA Acceptance For Its Quilience IND

Shares of Swiss clinical-stage pharmaceutical company NLS Pharmaceutics AG (NLSP) are climbing more than 4% Thursday morning.

NLS today said, the FDA has accepted its investigational new drug application (IND) for Quilience, the Company's lead drug candidate, for the treatment of narcolepsy.

The company plans to start Phase 2a study of Quilience in August 2021.

NLSP is at $3.13 currently. It has traded in the range of $2.06- $7.35 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT